Efgartigimod not checked
argenx · ARGX-113 · ARGX-113 PH20 SC
FollowEvery change as it happens, and a Monday email
Trials
21 active
48 in total · 24 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subcutaneous efgartigimod PH20 SC given by prefilled syringe”In the company’s words, NCT06558279 on ClinicalTrials.gov
- Tested for
- Generalized Myasthenia Gravis (5 trials), gMG (4 trials), Myasthenia Gravis (2 trials), Graves Disease (2 trials), AChR-Ab Seropositive Generalized Myasthenia Gravis (2 trials), New Onset Generalized Myasthenia Gravis (gMG), Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular and 26 more
- Main trialPhase 4
- “The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.”In the company’s words, NCT06909214 on ClinicalTrials.gov
- Other names
- ARGX-113 · ARGX-113 PH20 SC
Other drugs for Generalized Myasthenia Gravis
- GefurulimabAlexion Pharmaceuticals, Inc. · Phase 3
- B007Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
- Descartes-08Cartesian Therapeutics · Phase 3
- TelitaciceptRemeGen · Phase 3
- TelitaciceptVor Biopharma · Phase 3
- IptacopanNovartis · Phase 3
Coming up12
- Mar 2027Phase 2/3 trial completes · ClinicalTrials.gov
- 30 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- Sep 2027Phase 2/3 trial completes · ClinicalTrials.gov
- Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- 7 Mar 2028Phase 2 trial completes · ClinicalTrials.gov
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 28 Jul 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials48
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | Aug 2026 | A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) | |
| Phase 3Active, not recruiting | 30 Jun 2025 | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis | |
| Phase 3Active, not recruiting | 12 Jan 2026 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | |
| Phase 3Active, not recruiting | Jul 2027 | A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome | |
| Phase 3Active, not recruiting | Oct 2027 | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | |
| Phase 3Recruiting | Jun 2028 | A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia | |
| Phase 3Recruiting | Jun 2028 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease | |
| Phase 3Recruiting | Jun 2028 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. | |
| Phase 3Enrolling by invitation | Sep 2028 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy | |
| Phase 2/3Active, not recruiting | Mar 2027 | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | |
| Phase 2/3Recruiting | Sep 2027 | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | |
| Phase 2/3Recruiting | Oct 2028 | A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) | |
| Phase 2/3Enrolling by invitation | Sep 2029 | Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis | |
| Phase 2Active, not recruiting | 30 Apr 2027 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) | |
| Phase 2Recruiting | Oct 2027 | ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis | |
| Phase 2Active, not recruiting | Nov 2027 | A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) | |
| Phase 2Recruiting | 7 Mar 2028 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod | |
| Phase 2Not yet recruiting | 28 Jul 2028 | A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY) | |
| Phase 2Not yet recruiting | Jul 2030 | A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults | |
| Phase 4Completed | 19 Feb 2026 | A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC | |
| Phase 3Completed | 6 Apr 2020 | An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness | |
| Phase 3Completed | 2 Nov 2021 | Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis | |
| Phase 3Completed | 3 Feb 2022 | A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). | |
| Phase 3Completed | 23 Jun 2022 | A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. | |
| Phase 3Completed | 22 Aug 2023 | A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) | |
| Phase 3Completed | 24 Aug 2023 | An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis | |
| Phase 3Completed | 9 Oct 2023 | A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | |
| Phase 3Terminated | 25 Mar 2024 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) | |
| Phase 3Completed | 31 Dec 2024 | Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis | |
| Phase 3Terminated | 20 Mar 2025 | A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | |
| Phase 3Completed | 11 Mar 2026 | A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). | |
| Phase 2/3Completed | 13 Sep 2024 | A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | |
| Phase 2Completed | 20 Oct 2017 | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness | |
| Phase 2Completed | 9 Apr 2019 | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP | |
| Phase 2Completed | 29 Jan 2024 | A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) | |
| Phase 2Completed | 18 Apr 2024 | Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS | |
| Phase 2Terminated | 5 Aug 2024 | A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) | |
| Phase 2Terminated | 15 Aug 2024 | Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS | |
| Phase 2Completed | 3 Feb 2025 | Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome | |
| Phase 2Completed | 2 Jul 2025 | A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) | |
| Phase 1Completed | 15 Nov 2016 | IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers | |
| Phase 1Completed | 24 Dec 2020 | A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers | |
| Phase 1Completed | 8 Mar 2022 | Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV | |
| Phase 1Completed | 12 May 2023 | A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults | |
| Phase 1Completed | 12 Jun 2024 | A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod | |
| Phase 1Completed | 23 Sep 2026 | A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants | |
| Phase 2Authorised | not given | A double-blinded, randomized, placebo-controlled, multi-center trial of Efgartigimod in autoimmune dementia (EfgaDem) | |
| Phase 4Authorised | not given | Prospective experimental study to evaluate the efficacy and tolerability of efgartigimod as an early treatment in patients with generalised myasthenia gravis. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026